SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the availability of the Twist Comprehensive Viral Research Panel, a next-generation sequencing (NGS) panel that includes more than 3,000 viral genomes to enable identification of new and divergent viral species in a single sample. The panel will be bundled with an analysis platform from One Codex to enable an easy-to-use, complete end-to-end workflow that begins from the Twist library preparation and target enrichment panel and continues through publication-ready visualizations.
“With a renewed focus on public health and the impact of viral identification and containment, we are launching the Twist Comprehensive Viral Research Panel for researchers globally,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “We do not know when the next pandemic will arrive. Through tools like this, we can identify, detect, characterize and monitor an extensive range of viral diseases to inform societal decisions.”
About the Twist Comprehensive Viral Research Panel
This innovative product contains over one million unique probes to screen for 3,153 viral human and non-human pathogens. It is designed using sequences compiled from viral genomes across RefSeq, FluDB & VIPRdb databases and represents all viral families containing at least one virus known to infect humans. The panel covers all viral genome types (ssDNA, dsDNA, ssRNA, and dsRNA) and allows for quick capture and sequencing of unknown pathogens and highly divergent viral strains. The panel detects viral co-infections and can be used to differentiate between several viruses that may cause similar symptoms. Importantly, it can be used for metagenomic surveillance applications in complex sample types including stool.
An End-to-End Solution Including One Codex Platform
The Twist Comprehensive Viral Research Panel includes analysis on the One Codex platform allowing customers to generate easy-to-share publication-ready visuals and viral identification reporting for a complete solution from panel to results. One Codex is the leading bioinformatics platform for microbial genomics, supporting taxonomic and functional analysis of next-generation sequencing (NGS) data.
The product is available for Research Use Only. View the Product Sheet for more information.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; scientific unknowns and new information relating to the SARS-CoV-2 virus; the duration, extent and impact of the COVID-19 pandemic; supply chain and other disruptions caused by the COVID-19 pandemic or otherwise; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2020. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.